SCHEMBL6010765

SCHEMBL6010765

CC(O)(CN1CCN(C(=O)O)C(Cc2ccc(OC(F)(F)F)cc2)C1)Cn1cc([N+](=O)[O-])nc1Cl

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM1 P11229 2/20 0.39
KCNH2 Q12809 5/20 0.38
ABHD6 Q9BV23 1/20 0.38
DAGLA Q9Y4D2 1/20 0.38
PTGS1 P23219 1/20 0.35
SLC6A2 P23975 1/20 0.35
SLC6A4 P31645 1/20 0.35
CXCR3 P49682 1/20 0.34
ALDH1A1 P00352 1/20 0.32
TSHR P16473 1/20 0.32
LSS P48449 1/20 0.32
GRM2 Q14416 1/20 0.32
SCN9A Q15858 1/20 0.31
CYP2D6 P10635 1/20 0.31
SLC6A9 P48067 1/20 0.31
SLC6A5 Q9Y345 1/20 0.31
DRD2 P14416 1/20 0.31
DRD4 P21917 1/20 0.31
MCHR1 Q99705 1/20 0.31
HRH3 Q9Y5N1 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6010770 1.00 CHRM1 (0.39) CHRM1KCNH2ABHD6DAGLAPTGS1
SCHEMBL5538323 0.84 CHRM1 (0.41) CHRM1KCNH2PTGS1SLC6A2SLC6A4
SCHEMBL5538319 0.84 CHRM1 (0.41) CHRM1KCNH2PTGS1SLC6A2SLC6A4
SCHEMBL6010757 0.80 CHRM1 (0.41) CHRM1KCNH2ALDH1A1LSS
SCHEMBL58327 0.80 PTGS1 (0.44) CHRM1KCNH2PTGS1SLC6A2SLC6A4
SCHEMBL58326 0.80 PTGS1 (0.44) CHRM1KCNH2PTGS1SLC6A2SLC6A4
SCHEMBL6010645 0.79 KMT2A (0.35) ALDH1A1
SCHEMBL6010614 0.79 KMT2A (0.35) ALDH1A1
SCHEMBL6010621 0.79 KMT2A (0.35) ALDH1A1
SCHEMBL5540739 0.79 PTGS1 (0.48) CHRM1KCNH2PTGS1SLC6A2SLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 CHRM1 463/4885KCNH2 3503/4885ABHD6 4018/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.